Offspring of women with pregestational diabetes show markedly increased risk of birth defects (1) . While the cause of diabetic embryopathy is known to be multifactorial, previous investigations mainly focussed on the effect of maternal diabetes alone on the embryo. Genetic and environmental factors that can influence expressivity and penetrance of congenital malformations in diabetic pregnancies remain far from clear (2, 3) . Interestingly, some malformations found in the offspring of diabetic mothers (4) (5) (6) are very similar to those anomalies in humans and animals arising from exposure to excess retinoids (vitamin A and its analogues) (7) (8) (9) . For instance, a large-scale study of 18 population-based congenital anomaly registries shows that the odds ratio for caudal regression in diabetic versus non-diabetic pregnancy (odds ratio: 26.4; 95% confidence interval: 8.98-77.64) is well above other malformations (4) , which strengthens the conclusion of previous studies that caudal regression is a characteristic anomaly associated with diabetic pregnancy (5, 6) . Caudal regression also commonly occurs with retinoid teratogenesis in animal studies (9) (10) (11) .
Many of the functions of vitamin A in embryogenesis are mediated via its metabolite all-trans retinoic acid (RA), which is a key signalling molecule controlling the development of multiple organ systems. Different embryonic tissues/organs show variations in requirement for RA, thus tight regulation of local RA concentrations is critical to ensure precise levels of RA signalling required for normal embryo development. An important mechanism to control local RA concentrations is via catabolic inactivation by the CYP26 enzymes belonging to the cytochrome P450 family.
Three Cyp26 genes, namely Cyp26a1, b1 and c1, are expressed in specific embryonic tissues and attenuate deleterious effects of excessive RA signalling. Among them, CYP26A1 is the key RA catabolizing enzyme in many tissues and the only subtype that in other experiments. For crossing between ICR male and ICR female mice, all embryos at appropriate somite-stage from the same litter were pooled as one sample. For crossing between Cyp26a1 +/-male and ICR female mice, embryos were individually collected.
After DNA genotyping of the yolk sac by PCR using primers as described (14) , embryos of the same genotype (Cyp26a1 +/+ or Cyp26a1
) from the same litter were pooled as one sample. Total RNA was extracted from the whole embryo or tailbud (defined as the caudal end of the embryo up to one somite-length posterior to the last somite) samples using the RNeasy Mini Kit (Favorgen). An equal amount of RNA (250 ng) was reverse-transcribed into first-strand cDNA using the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems). The cDNA yielded from reverse transcription of 1.67 ng RNA was subjected to quantitative PCR using ABI 7900HT Fast Real-Time PCR system (Applied Biosystems), with SYBR Green PCR Master Mix (Applied Biosystems).
β-actin was used as internal control for normalization. The PCR conditions and primer sequences were listed in Supplementary Table 2 .
In Vitro RA Degrading Efficiency
Using an assay modified from Yamamoto (20) , four tailbuds of E9 embryos from the same litter were pooled as one sample and lysed in 5 µl of DMEM by trituration with a pipette tip, followed by 5 cycles of freezing in liquid nitrogen and thawing in a water bath at 37 o C for 1 min. The whole lysate was added to 50 µl of a reaction mixture containing 50 nM all-trans RA (Sigma-Aldrich), with or without 1.6 mg/ml NADPH (cofactor of cytochrome P450 enzyme), 0.3 mg/ml DTT (reducing agent for optimal cytochrome P450 enzyme function) and CYP26 specific inhibitor R115866 (21) at a concentration of 1, 10 or 100 nM in a culture medium (DMEM supplemented with 10% fetal bovine 7 serum). The reaction mixture was then incubated in a 5% CO 2 incubator at 37 o C for 2 h, during which the exogenous RA in the medium was degraded by the RA catabolizing enzyme in the tailbud lysate. After incubation, the amount of RA remaining was determined by adding the reaction mixture, diluted 30-fold with the culture medium, in triplicate to a 96-well plate containing RA reporter cells, which are F9 cells transfected with a RA response element that drives β-galactosidase expression (22) . Serially diluted RA standard solutions at concentrations from 10 -6 M to 10 -11 M were added in triplicate to the same 96-well plate. After culturing for 24 h, cells were stained with X-gal and the intensity of the blue product was measured using a microplate spectrophotometer. RA in the sample was quantified using a standard curve constructed with the serially diluted RA solutions (Supplementary Figure 1) .
In Vivo Clearance of RA
To determine in vivo efficiency of RA clearance, at various time points post-injection of 50 mg/kg body weight of RA at E9, the tailbud was collected under dim yellow light.
Tailbuds were individually placed in 300 µl of the culture medium added with 100 nM R115866 to inhibit endogenous CYP26 enzymes. After 24 h of incubation in 5% CO 2 at 37 o C, to allow maximum release of RA from the tailbud into the medium, RA in the medium was quantified using the RA reporter cell line. A preliminary study demonstrated that the culture conditions did not cause significant degradation of RA (Supplementary Figure 2) . To validate that RA measured using the RA reporter cell line measures RA released from tissues that can modulate RA levels, the tailbud of E9 embryos was collected 3 h post-injection of RA. The midbrain, which does not express any Cyp26 genes in untreated or RA-treated conditions, was also collected from these embryos as a control. Tissues from the same litter were pooled as one sample. RA in the sample was quantified using HPLC (23) .
Detection of Bioactive RA in Tailbud
The caudal-most portion of the tailbud of E9 embryo of MD and ND mice was excised under dim yellow light and individually placed on top of RA reporter cells grown on a 96-well plate in the culture medium added with 100 nM R115866 to inhibit endogenous CYP26 enzymes. After 24 h of culture, cells were stained with X-gal. The number of positively stained cells around the tailbud explant was counted under a stereomicroscope.
Susceptibility to RA Teratogenesis
The teratogenic effect of RA is dose-and stage-dependent (9) . To determine the susceptibility to RA teratogenesis, MD or ND mice at E8 or E9 received an intraperitoneal injection of 25 mg/kg RA or equivalent volume of suspension vehicle (peanut oil) as a control, and their embryos were examined at E13. Embryos treated with RA at E9 were examined for the extent of caudal truncation, which was expressed as the ratio of tail length to crown-rump length as used in our previous studies (18) . Embryos treated with RA at E8 were examined for exencephaly and spina bifida. Near-term E18 fetuses maternally treated with 40 mg/kg RA at E9 were examined for various types of renal malformations as described in our previous studies (24) . Maternal pre-conditioning with low dose RA (0.625 or 1.25 mg/kg) or suspension vehicle (peanut oil) as a control was achieved by oral gavage 2 h before receiving intraperitoneal injection of teratogenic 
Statistics
Statistical differences between two groups were analyzed by unpaired Student's t test.
Differences between multiple groups of data were analysed by one-way ANOVA, followed by Bonferroni post-hoc test, or by using Contrast test for assessing extent of differences. Dose response was analyzed by linear regression. The best-fit curves were compared by nonlinear regression. Data were presented as mean ± SEM, with P < 0.05 considered as statistically significant. All statistical analyses were conducted using the SPSS software (SPSS Inc.), except nonlinear regression analysis, which was conducted using the Prism software (GraphPad Software).
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RESULTS
Cyp26a1 Expression Levels and RA Degrading Efficiency are Reduced in Embryos of Diabetic Mice
During early mouse post-implantation development, Cyp26a1 is initially expressed in the headfold mesenchyme (Fig. 1A) , and then extends to the caudal neural plate and primitive streak (Fig. 1B) . As development proceeds, Cyp26a1 expression persists at the caudal end ( Fig. 1C and D) , now called the tailbud, which contains progenitor cells for forming various posterior structures. Rostrally, it is expressed in the craniofacial, cervical and branchial arch mesenchyme (Fig. 1C) . Embryos of manifestly diabetic (MD) mice exhibit a significant decrease in Cyp26a1 mRNA transcripts in all of these regions compared with embryos of non-diabetic (ND) mice ( Fig. 1A-E) . In contrast,
Cyp26b1
and Cyp26c1 are expressed predominantly in the cranial region but not in the tailbud ( Fig. 1F and H) , and show no significant difference in expression levels between embryos of MD and ND mice ( Fig. 1G and I ).
To determine whether a decrease in Cyp26a1 expression results in reduced efficiency of RA catabolism, we employed an in vitro assay to compare the RA degrading efficiency of the tailbud, which exclusively expresses Cyp26a1, but not Cyp26b1 and Cyp26c1, from E9 embryos of MD and ND mice. Results showed that only a low level of RA degrading activity was detected when tailbud lysate alone was applied ( Fig. 2A) . However, in the presence of NADPH and DTT for optimal activity of CYP26 enzymes, 66% of added RA was degraded within 2 h. In contrast, co-treatment with 1-100 nM of R115866, a potent CYP26-specific inhibitor (21) , resulted in a significant dose-dependent inhibition of RA degradation. Notably, while there was no significant difference in the protein content of the excised tailbuds from embryos of MD and ND mice (Supplementary Figure 3) , tailbud lysate of the MD group exhibited only 45% of activity of the ND group.
To further compare the efficiency of in vivo clearance of RA, MD and ND mice were injected with an exogenous dose of 50 mg/kg RA at E9, followed by measurement of RA in individual tailbuds at hourly intervals using the RA reporter cell line (Fig. 2B) , which showed results comparable with quantification of RA using HPLC (Supplementary Table 3 ). Despite a similar response time-course in MD and ND groups, the amount of RA in tailbuds of the MD group was significantly higher than the ND group at all time-points studied ( Figure 4B) .
RA Levels are Increased in Tailbuds of Embryos of Diabetic Mice
To determine whether reduction in RA degrading efficiency would lead to a rise in endogenous RA levels, we excised the caudal-most part of the tailbud (Fig. 3A) furthest away from the RA source in adjacent trunk tissues, and put it directly on the RA reporter cells to detect bioactive RA release (22) . Reporter cells exposed to RA expressed β-galactosidase and turned blue with X-gal staining. There were hardly any positively stained cells around tailbuds from embryos of ND mice ( Fig. 3B and C) , which agrees with previous findings that the tailbud is normally devoid of RA (26) . However, stained cells were observed around more than half the tailbuds from embryos of MD mice. The number of stained cells varied from under 10 to over 40, implying a varying magnitude of elevation of RA level in tailbuds of diabetes-exposed embryos.
Several genes including Fgf8, Wnt3a and Cdx2 are indispensable key players in caudal development (27) . Excessive RA has been demonstrated to down-regulate these genes and cause axial truncation (11, 26, 28) . However, of these genes, only Fgf8 was significantly down-regulated in the tailbud of embryos of MD mice ( Cyp26a1 is highly inducible by RA. However, the magnitude of up-regulation of Cyp26a1 in tailbuds of the MD group was significantly less than the ND group (P < 0.05, Contrast test), which further exacerbated the difference between these two groups.
Concomitantly, there was a marked down-regulation of Fgf8, with expression levels in tailbuds of the RA-treated MD group reduced to less than one-third of the ND group without RA treatment (Fig. 4C ). Consistent with our previous findings (18) , though there
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was no difference in Wnt3a expression levels between tailbuds of MD and ND groups at steady-state (Fig. 4A) , upon RA challenge, Wnt3a was down-regulated to a significantly greater extent in tailbuds of the MD group than the ND group (Fig. 4C) . Similarly, the MD group showed increased propensity to RA-induced down-regulation of Cdx2.
RA action is mediated via transactivation by retinoic acid receptors (Rar) that heterodimerize with retinoid X receptors (Rxr). In the mouse embryo, Rarγ and Rxrα mediate the teratogenic effect of RA in inducing caudal truncation (29, 30) . However, there were no differences in expression levels of Rarγ and Rxrα between tailbuds of embryos of ND and MD mice at steady-state (Fig. 4A ) or 4 h post-injection of RA ( Fig.   4C ). Together, these findings support the idea that enhanced down-regulation of caudal regulatory genes in tailbuds of embryos of MD mice is due to increased RA levels resulting from reduced efficiency of RA degradation, rather than secondary to differences in efficiency of transactivation via the RA receptors.
Genetic Reduction of Cyp26a1 Exacerbates Susceptibility of Embryos of Diabetic
Mice to RA Teratogenesis
We asked whether a decrease in Cyp26a1 expression leads directly to reduced efficiency of RA clearance, and whether functional loss of Cyp26a1 could interact with the maternal diabetic environment to influence RA degrading efficiency and susceptibility to RA teratogenesis. To investigate these questions, we crossed Cyp26a1 +/-male mice with MD or ND female mice. We hypothesized that Cyp26a1 +/-mutant embryos would exhibit a lower RA degrading efficiency than their Cyp26a1 +/+ wild-type littermates and that exposure to maternal diabetes would exacerbate these genetic differences.
Indeed, E9 embryos from different genotype-maternal environment combinations showed prominent differences in Cyp26a1 levels ( Fig. 5E ). TL/CRL ratio was used as a 'surrogate' both for regression of multiple caudal structures in mice and for the analogous 'caudal regression' process that affects species without tails, such as humans. In addition to caudal truncation, renal malformations are commonly associated with caudal regression (15, 16) . Indeed, we also found a twelve-fold increase in incidence ( Fig. 5F ) and severity (Table 1) of renal malformations in near-term Cyp26a1 +/-fetuses exposed to maternal diabetes compared with wild-type fetuses in non-diabetic pregnancy when being challenged with a teratogenic dose of RA.
Enhancing RA Degrading Efficiency Counteracts Increased Susceptibility to RA Teratogenesis Induced by Maternal Diabetes
Cyp26a1 is highly RA-inducible, as it contains multiple RA response elements (31) . Thus, as a proof-of-principle, we attempted to 'pre-condition' embryos of MD mice by using an Page 14 of 47 Diabetes exogenous sub-teratogenic RA dose to up-regulate Cyp26a1 expression, in order to determine whether pre-conditioning could lead to a protective effect against RA teratogenesis. Previous findings showed that maternal oral administration of 2.5 mg/kg RA is sufficient to achieve near full rescue of mid-gestation mouse embryos lacking Raldh2, the principal RA synthetic enzyme (32) . Therefore, we pre-conditioned pregnant mice with 0.625 or 1.25 mg/kg RA via oral feeding. These dosages are far below the teratogenic concentration range, but yielded a dose-dependent increase in Cyp26a1 mRNA levels in tailbuds of embryos by 2 h after administration (Fig. 6A) . Notably, supplementation with 0.625 mg/kg RA did not induce changes in Fgf8, Wnt3a and Cdx2 expression (Supplementary Figure 6) , but up-regulated the expression of Cyp26a1 in tailbuds of the MD group to a level similar to that of the ND group fed with vehicle ( Fig.   6A) , with a concomitant normalization of RA degrading efficiency (Fig. 6B) . Then, when maternally challenged with an intraperitoneal injection of a teratogenic dose of 25 mg/kg RA, we found the severity of caudal truncation to be significantly reduced, as shown by the significantly higher TL/CRL ratio in embryos of RA-pre-conditioned mice than in embryos from vehicle-fed mice in both MD and ND conditions (Fig. 6C) . Even the higher (1.25 mg/kg) pre-conditioning dose of RA was non-teratogenic and by itself did not affect the TL/CRL ratio of the embryo. While it could have had other effects on the embryo, in addition to up-regulating Cyp26a1, the highly comparable pattern of dose-dependent up-regulation of Cyp26a1 and dose-dependent increase in the TL/CRL ratio, in the absence of changes in the key caudal regulatory genes, suggests a specific effect of pre-conditioning. These findings support the idea that pre-conditioning the embryo via enhancing RA degrading efficiency can offer a protective effect against RA teratogenesis and abolish the increased propensity of embryos from diabetic pregnancy to Amongst the most frequent congenital anomalies associated with maternal diabetes are neural tube defects (NTDs) (4) . Expression levels of Cyp26a1 in the cranial mesenchyme and the caudal neural plate are prominently reduced in E8 embryos of MD mice (Fig. 1B) . Moreover, Cyp26a1 -/-embryos exhibit exencephaly and spina bifida (13, 14) , suggesting the importance of CYP26A1 enzyme in protecting these tissues from the deleterious effects of ectopic RA signalling. We found that injection of 25 mg/kg of RA at E8 induced around 6.7% exencephaly (Fig. 7A ) and 4.4% spina bifida (Fig. 7B ) in
Cyp26a1
+/+ embryos of ND mice. However, the incidence of RA-induced exencephaly and spina bifida was markedly increased by six-and seven-fold respectively in Cyp26a1 +/+ embryos exposed to diabetes. Similar trend was found in embryos of ICR x ICR background (Supplementary Figure 7) . The penetrance of NTDs was further exacerbated to 75.0% exencephaly and 71.3% spina bifida in Cyp26a1 +/-embryos of MD mice with a pre-existing genetic defect of RA catabolism. Similar to caudal truncation, the increase in susceptibility to RA-induced exencephaly and spina bifida caused by maternal diabetes was significantly reduced when embryos were pre-conditioned by maternal feeding of low dose RA. Together, these findings support the idea that deregulated RA catabolism resulting from reduced levels of Cyp26a1 expression acts to sensitize embryos of diabetic pregnancy to fluctuations in RA levels.
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DISCUSSION
In the present study, we found that the embryonic expression of the key RA catabolizing enzyme Cyp26a1 is significantly down-regulated under maternal diabetes. This leads to a decrease in RA inactivation efficiency and enhances the deleterious effect of excessive RA signalling on key caudal regulatory genes, such as Fgf8, Wnt3a and Cdx2, which are required for continued axial elongation (27) . We previously demonstrated that enhanced RA-induced down-regulation of Wnt3a exacerbated apoptosis in the tailbud of mouse embryos exposed to a diabetic or hyperglycemic condition, leading to premature termination of caudal development (18, 33) . This resulted in absence of lower vertebrae, imperforate anus, clubfeet, renal and caudal spinal cord malformations, all of which are commonly associated with caudal regression (10, 11, (15) (16) (17) .
The most frequent anomalies in pregnancies complicated by pregestational diabetes are NTDs and congenital heart defects (CHDs) (4, 5) . Results of this study support the idea that a decrease in Cyp26a1 expression also significantly increases the propensity of embryos from diabetic pregnancy to exencephaly and spina bifida when RA homeostasis is perturbed. Although we have not examined heart development, Cyp26a1 is expressed in the cardiac neural crest cells, primitive heart tube and outflow tract, and
Cyp26a1
-/-embryos exhibit CHDs (13, 14) . Specific subgroups of CHD associated with improper RA signalling (8, 9) are highly similar to those showing increased frequencies in the offspring of mothers with pregestational diabetes (4, 34) . As tight regulation of RA signalling is critical for many developmental processes, deregulated RA catabolism in early embryonic life can perturb the development of multiple organ systems, which is in line with the finding that specific multiple congenital anomalies are common in affected 
obesity, diabetes and related complications (42). A well-known example is isotretinoin
Page 18 of 47 Diabetes (13-cis RA) prescribed for treatment of severe acne. It has been shown that the teratogenic threshold for isotretinoin is much lower in humans (0.5 mg/kg) (43) than in mice (100 mg/kg) (44). Human embryos are highly sensitive to isotretinoin, with a pattern of malformations (8) similar to that seen in animals exposed to all-trans RA teratogenesis (9) . In fact, the teratogenic effect of 13-cis RA has been demonstrated in animals and suggested for humans to be mediated via its conversion to all-trans RA, which then binds to the nuclear RA receptors to regulate gene expression (45). Moreover, our previous (18) and present studies show that maternal diabetes can enhance RA teratogenicity. Thus the teratogenic threshold for isotretinoin in embryos of women with pregestational diabetes may be even lower than the 0.5 mg/kg figure previously quoted (43).
Other than direct exposure to retinoids, medications, such as the anti-convulsant valproic acid, and fluconazole for treating fungal and yeast infections, have been shown to increase embryonic RA levels and induce malformations (46,47). Maternal smoking may also impose increased risk since recent studies suggest that the teratogenic effect of nicotine on embryonic development is highly associated with suppression of Cyp26a1 and perturbation of RA signalling (48). In fact, many chemicals can modulate RA homeostasis. As such, neural tube and axial defects mediated by modulation of RA homeostasis is proposed to be adopted as an Adverse Outcome Pathway (AOP) framework for assessing developmental toxicity of chemicals (49).
There is a global trend that type 2 diabetes increasingly affects children and adolescents (50). As the prevalence of diabetes in women of childbearing age continues to rise, the number of pregnancies complicated by pregestational diabetes is likely to increase exponentially. The partial penetrance and variable expressivity of diabetic at E9 (n = 5 from 5 litters). *P < 0.05; **P < 0.01; ***P < 0.001, one-way ANOVA followed by Bonferroni test. Error bars represent mean ± SEM. fetuses were examined for renal malformations (n = 11 litters). *P < 0.05; **P < 0.01; ***P < 0.001, one-way ANOVA followed by Bonferroni test. Error bars represent mean ± SEM. RA was stable at 37°C for 24 h. RA was added to the culture medium at a concentration of 10 nM. The medium was either immediately frozen and stored at -80°C (n = 4) or incubated at 37°C for 24 h in a 5% CO 2 incubator (n = 4). The RA concentrations of the two groups of samples were then determined by the RA reporter cell line. There was no significant degradation of RA in the sample that had been incubated at 37°C for 24 h when compared with the immediately frozen sample.
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Immediately frozen The midbrain, which does not express any of the three Cyp26 genes, exhibits no difference in RA levels between embryos of diabetic and non-diabetic mice after RA treatment. A: In situ hybridization on E9 embryos demonstrates that all three Cyp26 genes (Cyp26a1, Cyp26b1 and Cyp26c1) do not express in the midbrain (MB) with or without (No RA) being maternally treated with 50 mg/kg RA (50RA). Scale bar = 0.4 mm. B: Amount of RA in the tailbud and midbrain of E9 embryos 3 h post-injection of 50RA, measured using HPLC (n = 7-9 from 7-9 litters). The tailbud of embryos of manifestly diabetic (MD) mice with reduced Cyp26a1 expression had a significantly greater amount of RA than in embryos of non-diabetic (ND) mice. In contrast, the midbrain, without Cyp26 expression, showed no difference in the amount of RA between embryos of MD and ND mice. *P < 0.001, Student's t test. Error bars represent mean ± SEM. Figure 6 . Oral feeding of low dose RA does not cause any change in expression of key genes for caudal development. Quantification of mRNA levels of various caudal regulatory genes, normalized to β-actin, and expressed relative to ND (CON), which was set as 1, in tailbuds of E9 embryos of non-diabetic (ND) and manifestly diabetic (MD) mice, 2 h after oral feeding with low dose 0.625 mg/kg RA (0.625RA) or vehicle as control (CON) (n = 5 from 5 litters). No significant changes in mRNA levels were associated with low dose RA treatment. *P < 0.05, one-way ANOVA followed by Bonferroni test. Error bars represent mean ± SEM. . In untreated conditions, only 3% of embryos of MD mice developed exencephaly. However, when challenged with 25RA, a dose that only induced exencephaly in 3% of embryos of ND mice, embryos of MD mice were significantly more susceptible to RA teratogenesis and exhibited a nine-fold increase in the incidence rate of exencephaly. *P < 0.001, one-way ANOVA followed by Bonferroni test. Error bars represent mean ± SEM.
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